{
    "organizations": [],
    "uuid": "952f6bb5996a99653bf00bf16f4f7a4ca674237f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-glaxosmithkline-says-nucala-study/brief-glaxosmithkline-says-nucala-study-reports-long-term-safety-data-consistent-exacerbation-reduction-improved-asthma-control-idUSFWN1SS01D",
    "ord_in_thread": 0,
    "title": "BRIEF-GlaxoSmithKline Says Nucala Study Reports Long-Term Safety Data, Consistent Exacerbation Reduction, Improved Asthma Control",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 21 (Reuters) - GlaxoSmithKline PLC:\n* NUCALA (MEPOLIZUMAB) STUDY REPORTS LONG-TERM SAFETY DATA, CONSISTENT EXACERBATION REDUCTION AND IMPROVED ASTHMA CONTROL\n* NEW STUDY SHOWED ONE THIRD OF PATIENTS HAD NO EXACERBATIONS ON LONG-TERM TREATMENT WITH NUCALA Further company coverage:\n ",
    "published": "2018-05-21T15:13:00.000+03:00",
    "crawled": "2018-05-22T19:32:57.007+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "glaxosmithkline",
        "plc",
        "nucala",
        "mepolizumab",
        "study",
        "report",
        "safety",
        "data",
        "consistent",
        "exacerbation",
        "reduction",
        "improved",
        "asthma",
        "control",
        "new",
        "study",
        "showed",
        "one",
        "third",
        "patient",
        "exacerbation",
        "treatment",
        "nucala",
        "company",
        "coverage"
    ]
}